Active	Status	Sponsor type	Region	Phase	Filter
23 Active 8 Inactive 31 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Couriel, Daniel M
NCT02867384: Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation	Active, not recruiting	2	181	US	Obinutuzumab, Gazyva, Placebo	Dana-Farber Cancer Institute, Roche-Genentech	Graft vs. Host Disease	11/23	10/24
Lee, Catherine
FLIGHT, NCT04446182: Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Jul 2022 - Dec 2022 : Data from part-1 of P2 FLIGHT trial for cGVHD	Terminated	2	3	US	Itacitinib, INCB039110, Extracorporeal Photopheresis (ECP), ECP	University of Utah, Incyte Corporation	Chronic Graft-versus-host-disease	03/22	01/23
JSP-CP-003, NCT04429191: JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation	Recruiting	1	40	US	Humanized anti-CD117 Monoclonal Antibody (JSP191), JSP191	Jasper Therapeutics, Inc.	MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML	10/23	12/23
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients	Available	N/A		Canada, US, RoW	CTL019, tisagenlecleucel, Kymriah	Novartis Pharmaceuticals	Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
Stephens, Deborah
NCT06043674: A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation	Recruiting	2	66	US	Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Polatuzumab Vedotin, Atezolizumab, Tecentriq, Tocilizumab, Actemra	Christine Ryan, Genentech, Inc.	Chronic Lymphocytic Leukemia, Richter's Transformation	01/28	01/33
NCT03492125: A Study of the Selective PKC-β Inhibitor MS- 553	Terminated	1/2	63	US	MS-553, acalabrutinib, venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, obinutuzumab, Gazyva	MingSight Pharmaceuticals, Inc	Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma	11/23	11/23
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL From TRANSCEND-CLL-004 trial in CLL at ASH 2019 Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019 Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL Presentation of P1 data from P1/2 trial for CLL at ASH 2018 Dec 2018 - Dec 2018: Presentation of P1 data from P1/2 trial for CLL at ASH 2018 From TRANSCEND-CLL-004 trial in CLL at ASH 2018 [screenshot] Dec 2018 - Dec 2018: From TRANSCEND-CLL-004 trial in CLL at ASH 2018 [screenshot] More	Recruiting	1/2	320	Canada, US	JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax	Juno Therapeutics, a Subsidiary of Celgene	Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic	11/27	11/27
Hu, Boyu
NCT04673617: AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Recruiting	1/2	108	US	AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine	Artiva Biotherapeutics, Inc.	Non Hodgkin Lymphoma	11/24	11/24
MPCT-012L, NCT05826535: Study of IMPT-314 in R/R Aggressive B-cell NHL	Recruiting	1/2	150	US	IMPT-314	ImmPACT Bio	Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma	06/25	12/29
CORONADO CLL, NCT05405309: RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia	Terminated	1/2	5	US	RP-3500, Olaparib	University of Utah, Repare Therapeutics	Chronic Lymphocytic Leukemia	10/23	10/24